- Acadia Pharmaceuticals announced that the European Commission has granted marketing authorization for DAYBU (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in adults and children aged five and older, making it the first approved therapy for this condition across the European Union, Iceland, Liechtenstein, and Norway.
- This approval, based on Phase 3 LAVENDER data showing meaningful improvements in core Rett symptoms, opens a new rare-disease market for Acadia in Europe while the company now enters country-by-country pricing and reimbursement negotiations.
- We’ll now examine how securing EU-wide approval for DAYBU, the first Rett syndrome treatment, could reshape ACADIA’s broader investment narrative.
We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
ACADIA Pharmaceuticals Investment Narrative Recap
To own ACADIA, you have to believe it can turn a concentrated neurology and rare-disease portfolio into durable, diversified cash flows despite pricing and competitive pressures. The new EU approval for DAYBU expands its Rett footprint beyond the U.S., but in the near term the key catalyst remains execution on DAYBU adoption and reimbursement quality, while the biggest risk is still the company’s dependence on NUPLAZID and DAYBUE for the bulk of revenues and earnings.
The most relevant recent development alongside the EU decision is ACADIA’s August 2026 guidance raise, which lifted expected 2026 total revenue to US$1.24–US$1.30 billion, including US$480–US$510 million in global DAYBUE sales. That earlier guidance did not factor in formal EU marketing authorization, so investors now have to weigh how EU pricing and reimbursement outcomes could adjust both expectations for DAYBU’s contribution and the pace of any future guidance changes.
Yet while DAYBU’s EU win broadens the investment case, investors should be aware that revenue is still heavily concentrated in just two drugs and...
Read the full narrative on ACADIA Pharmaceuticals (it's free!)
ACADIA Pharmaceuticals' narrative projects $1.7 billion revenue and $317.1 million earnings by 2029. This requires 13.5% yearly revenue growth and a $63.4 million earnings decrease from $380.5 million today.
Uncover how ACADIA Pharmaceuticals' forecasts yield a $33.25 fair value, a 19% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts already expected revenue near US$1.9 billion and earnings around US$573.7 million by 2029, so if you worry that heavy dependence on NUPLAZID and DAYBUE could backfire, remember these forecasts reflect a far more bullish view than the consensus and may shift again as the new EU approval for DAYBU is absorbed.
Explore 6 other fair value estimates on ACADIA Pharmaceuticals - why the stock might be worth 27% less than the current price!
The Verdict Is Yours
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your ACADIA Pharmaceuticals research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free ACADIA Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ACADIA Pharmaceuticals' overall financial health at a glance.
Searching For A Fresh Perspective?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Find 47 companies with promising cash flow potential yet trading below their fair value.
- Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com